Xingqi Pharmaceutical announced that the Phase II clinical trial of its SQ-22031 eye drops for the treatment of neurotrophic keratitis has yielded a clinical study report. The trial results showed that the high-dose group of SQ-22031 eye drops demonstrated superior efficacy benefits and a favorable safety profile, supporting the high dose as the proposed dose for the Phase III clinical trial. As of the announcement date, no similar drug has been approved for marketing in China, and this drug is a Class 1 therapeutic biological product. This report will not have a significant impact on the company's near-term performance.
Shenyang Xingqi Pharmaceutical Co LtdPositive Phase II results for SQ-22031 eye drops, a novel Class 1 therapeutic biological product for neurotrophic keratitis, with no similar drug approved in China.